Transcript: Protalix BioTherapeutics Q1 2026 Earnings Conference Call

Benzinga APIs supply real-time entree to net telephone transcripts and fiscal data. Visit https://www.benzinga.com/apis/ to larn more.

View the webcast astatine https://viavid.webcasts.com/starthere.jsp?ei=1762414&tp_key=330c698581

Summary

Protalix BioTherapeutics reported a $25 cardinal milestone outgo from Chiesi owed to European Commission support of a caller dosing regimen for El Fabrio, ending the 4th with $51 cardinal successful cash.

The institution reaffirmed its 2026 gross guidance of $78 to $83 million, with cardinal gross drivers being El Fabrio and PRX115's Phase 2 survey and ongoing partnerships.

The institution plans to seizure 15-20% of the planetary Fabry marketplace by 2031, with strategical absorption connected expanding El Fabrio's beingness successful Europe and advancing PRX115 for uncontrolled gout.

First-quarter gross was $33.8 million, with an summation successful R&D expenses to $5.4 cardinal owed to the PRX115 Phase 2 study, portion maintaining a beardown fiscal presumption with nary debt.

Management expressed assurance successful achieving semipermanent maturation done strategical partnerships and pipeline advancement, with expectations for important gross maturation successful the 2nd fractional of 2026.

Full Transcript

OPERATOR

. Good greeting ladies and gentlemen and invited to Protalix BioTherapeutics First Quarter 2026 Financial and Business Results Conference Call. As a reminder, this league is being recorded. I volition present crook the league implicit to our host, Mr. Mike Moyer of LASCI Advisors, Investor Relations for Protalix. Thank you. Please spell ahead.

Mike Moyer (Investor Relations)

Thank you Operator and invited to Protalix BioTherapeutics Q1 2026 fiscal results and Business Update Conference Call. With maine contiguous are Dror Bashan, President and CEO of Protalix, and Gilad Mamlach, Senior Vice President and Chief Financial Officer. A property merchandise announcing the fiscal results and firm updates were issued this greeting and are disposable present connected the Protalix website. Please instrumentality a infinitesimal to work the disclaimer astir guardant looking statements successful the property release. The net merchandise and this teleconference see guardant looking statements. These guardant looking statements are taxable to known and chartless risks and uncertainties. They whitethorn origin existent results to disagree materially from the statements made. Factors that could origin existent results to disagree are described successful the disclaimer and successful Protalix's filings with the U.S. securities and Exchange Commission. I volition present crook the telephone implicit to Mr. Dror Bashan.